Treatment type | p-val | Pathway affected |
---|---|---|
HT-29 | Â | Â |
E | 0,0127 | Parkinson's disease |
 | 0,0216 | Bisphenol A degradation |
 | 0,027 | Nucleotide sugars metabolism |
 | 0,028 | ECM-receptor interaction |
 | 0,029 | Ubiquitin mediated proteolysis |
 | 0,03 | Neurodegenerative disorders |
 | 0,03 | Prion disease |
 | 0,03 | mTOR signaling pathway |
Cx10 | 0,0001 | Ribosome |
 | 0,0288 | Calcium signaling pathway |
 | 0,0467 | Prion disease |
Gb | 0,0056 | T cell receptor signaling pathway |
 | 0,0115 | mTOR signaling pathway |
 | 0,0163 | Natural killer cell mediated cytotoxicity |
 | 0,0187 | Pentose and glucuronate interconversions |
 | 0,0202 | Tight junction |
 | 0,0214 | Starch and sucrose metabolism |
 | 0,0242 | Insulin signaling pathway |
 | 0,0293 | Long-term potentiation |
 | 0,0332 | GnRH signaling pathway |
 | 0,0352 | TGF-beta signaling pathway |
 | 0,0402 | MAPK signaling pathway |
 | 0,0482 | D-Glutamine and D-glutamate metabolism |
 | 0,0497 | Cell Communication |
Cx10 + E | 0,0001 | Oxidative phosphorylation |
 | 0,0211 | Benzoate degradation via hydroxylation |
 | 0,0254 | Chronic myeloid leukemia |
 | 0,0277 | Antigen processing and presentation |
 | 0,0319 | Ribosome |
 | 0,0461 | Notch signaling pathway |
Gb + E | 0,0002 | Cholera – Infection |
 | 0,0003 | PPAR signaling pathway |
 | 0,0075 | Tyrosine metabolism |
 | 0,0090 | Fluorene degradation |
 | 0,0126 | Benzoate degradation via hydroxylation |
 | 0,0197 | Insulin signaling pathway |
 | 0,0205 | Fatty acid metabolism |
 | 0,0208 | Calcium signaling pathway |
 | 0,0225 | Neuroactive ligand-receptor interaction |
 | 0,0338 | Oxidative phosphorylation |
 | 0,0351 | Glycerolipid metabolism |
 | 0,0385 | Glioma |
 | 0,0428 | Urea cycle and metabolism of amino groups |
 | 0,0442 | Neurodegenerative disorders |
 | 0,0442 | Styrene degradation |
 | 0,0442 | Fatty acid biosynthesis |
 | 0,0445 | 1- and 2-Methylnaphthalene degradation |
Caco-2 | Â | Â |
E | 0,0022 | Epithelial cell signaling in Helicobacter pylori infection |
 | 0,0034 | Tight junction |
 | 0,0133 | Adherent junction |
 | 0,0152 | Dentatorubropallidoluysian atrophy (DRPLA) |
 | 0,0179 | Apoptosis |
 | 0,0422 | Methionine metabolism |
 | 0,0436 | D-Glutamine and D-glutamate metabolism |
 | 0,0445 | Selenoamino acid metabolism |
 | 0,0481 | Glycan structures – biosynthesis 2 |
 | 0,0496 | Toll-like receptor signaling pathway |
Cx10 | 0,0008 | Oxidative phosphorylation |
 | 0,0134 | Ribosome |
 | 0,0179 | Cell cycle |
 | 0,0193 | Metabolism of xenobiotics by cytochrome P450 |
 | 0,0356 | Glycan structures – biosynthesis 1 |
 | 0,0489 | O-Glycan biosynthesis |
Gb | 0,0001 | Ribosome |
 | 0,0106 | Basal cell carcinoma |
 | 0,0135 | Cell Communication |
 | 0,0308 | Valine, leukine and isoleukine degradation |
 | 0,0394 | Fatty acid metabolism |
Cx10 + E | 0.0141 | Gap junction |
 | 0.0163 | GnRH signaling pathway |
 | 0.0169 | ECM-receptor interaction |
 | 0.0364 | Vitamin B6 metabolism |
Gb + E | 0,0183 | C5-Branched dibasic acid metabolism |
 | 0,0369 | Tight junction |